About Small ribosomal subunit protein uS9m
Small ribosomal subunit protein uS9m (MRPS9) is a protein
from Homo sapiens identified by UniProt accession
P82933, 396 residues long.
MolForge cross-references it against 0 known binders and
13 disease associations.
Target properties
| Protein name | Small ribosomal subunit protein uS9m |
|---|
| UniProt accession | P82933 |
|---|
| Gene | MRPS9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 396 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (13)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- bone density · score 0.25
- urate measurement · score 0.25
- type 2 diabetes mellitus · score 0.07
- systemic juvenile idiopathic arthritis · score 0.02
- ovarian carcinoma · score 0.01
- Alzheimer disease · score 0.01
- cancer · score 0.00
- pancreatic ductal adenocarcinoma · score 0.00
- Intestinal epithelial dysplasia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P82933-F1 | alphafold | PREDICTED | 82.06 | — |
Amino-acid sequence (396 residues)
MAAPCVSYGG AVSYRLLLWG RGSLARKQGL WKTAAPELQT NVRSQILRLR HTAFVIPKKN VPTSKRETYT EDFIKKQIEE FNIGKRHLAN MMGEDPETFT QEDIDRAIAY LFPSGLFEKR ARPVMKHPEQ IFPRQRAIQW GEDGRPFHYL FYTGKQSYYS LMHDVYGMLL NLEKHQSHLQ AKSLLPEKTV TRDVIGSRWL IKEELEEMLV EKLSDLDYMQ FIRLLEKLLT SQCGAAEEEF VQRFRRSVTL ESKKQLIEPV QYDEQGMAFS KSEGKRKTAK AEAIVYKHGS GRIKVNGIDY QLYFPITQDR EQLMFPFHFV DRLGKHDVTC TVSGGGRSAQ AGAIRLAMAK ALCSFVTEDE VEWMRQAGLL TTDPRVRERK KPGQEGARRK FTWKKR
Explore Small ribosomal subunit protein uS9m with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets